Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMARIN CORPORATION PLC

(AMRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

06/21/2021 | 09:31am EDT

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's Laboratories Ltd.

The justices declined to hear Dublin-based Amarin Pharma's appeal of a lower court ruling that affirmed that the patents were invalid following a challenge by Hikma and Dr. Reddy's. The lower court found that the patents were invalid as "obvious" based on "prior art," which means that earlier publications had already disclosed their innovations.

A federal judge's decision last year to invalidate the patents cost Amarin Corp nearly 70% of its stock price. (Reporting by Blake Brittain; Editing by Will Dunham)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AMARIN CORPORATION PLC 2.28% 4.03 Delayed Quote.-19.43%
DR. REDDY'S LABORATORIES LIMITED -10.44% 4844.35 End-of-day quote.-6.91%
HIKMA PHARMACEUTICALS PLC -0.04% 2615 Delayed Quote.3.89%
All news about AMARIN CORPORATION PLC
07/21European ADRs Move Sharply Higher in Wednesday Trading
MT
07/19European ADRs Down 2.3% as Stock Markets Slump Monday
MT
07/15AMARIN : to Report Second Quarter and Six Month 2021 Financial Results and Host ..
AQ
07/14European ADRs Nudge Higher in Wednesday Trading
MT
07/12European ADRs Move Higher in Monday Trading
MT
07/08European ADRs Move Sharply Lower in Thursday Trading
MT
07/02AMARIN : Reports Second Quarter 2015 Financial Results and Provides Update on Op..
PU
07/02AMARIN : Reports First Quarter 2015 Financial Results and Provides Update on Ope..
PU
07/02AMARIN : Reports Fourth Quarter and Year-End 2014 Financial Results and Provides..
PU
07/02AMARIN : Reports Second Quarter 2014 Financial Results and Provides Update on Op..
PU
More news
Financials (USD)
Sales 2021 640 M - -
Net income 2021 -41,2 M - -
Net cash 2021 377 M - -
P/E ratio 2021 -33,1x
Yield 2021 -
Capitalization 1 555 M 1 555 M -
EV / Sales 2021 1,84x
EV / Sales 2022 1,58x
Nbr of Employees -
Free-Float 94,9%
Chart AMARIN CORPORATION PLC
Duration : Period :
Amarin Corporation plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMARIN CORPORATION PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 3,94 $
Average target price 9,78 $
Spread / Average Target 148%
EPS Revisions
Managers and Directors
John F. Thero President, Chief Executive Officer & Director
Michael W. Kalb Chief Financial Officer & Senior Vice President
Lars G. Ekman Non-Executive Chairman
Steven B. Ketchum Chief Scientific Officer & Senior Vice President
Craig B. Granowitz Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AMARIN CORPORATION PLC-19.43%1 824
GILEAD SCIENCES, INC.18.01%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS19.60%57 013
BIONTECH SE251.15%55 555
VERTEX PHARMACEUTICALS-15.83%50 308